Literature DB >> 1710569

A highly selected panel of anti-CD4 antibodies fails to induce anti-idiotypic antisera mediating human immunodeficiency virus neutralization.

D G Healey1, L Dianda, D Buck, K Schroeder, A Truneh, Q J Sattentau, P C Beverley.   

Abstract

Anti-CD4 antibodies directed to the N terminus of CD4 can inhibit human immunodeficiency virus (HIV) infection. Therefore, it has been proposed that some of these reagents may contain idiotypic determinants which conformationally model the binding site expressed on gp120. In this report, we have selected a panel of anti-CD4 monoclonal antibodies as idiotypic mimics of gp120 by employing cross-blocking techniques, and CD4 epitope mapping using site-directed mutagenesis. These studies suggest that only 4 out of the original panel of 12 would be expected to represent suitable candidates for modelling the gp120 binding site. Nevertheless, anti-idiotypic antisera raised against these antibodies failed to inhibit gp120 binding to CD4. This negative result may reflect the incomplete modelling of the virus binding site by anti-CD4, or the lack of internal image antibody in the anti-idiotypic preparations. Alternatively, the binding site on gp120 may not be accessible to antibody neutralization, excluding the possibility of an idiotypic vaccine to HIV based on anti-CD4 antibody as surrogate antigen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710569     DOI: 10.1002/eji.1830210624

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Construction of a binding site for human immunodeficiency virus type 1 gp120 in rat CD4.

Authors:  G A Schockmel; C Somoza; S J Davis; A F Williams; D Healey
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

Review 2.  Virus receptors: implications for pathogenesis and the design of antiviral agents.

Authors:  L C Norkin
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys.

Authors:  C Y Kang; P Nara; S Chamat; V Caralli; A Chen; M L Nguyen; H Yoshiyama; W J Morrow; D D Ho; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

4.  Human immunodeficiency virus gp120 binding C'C" ridge of CD4 domain 1 is also involved in interaction with class II major histocompatibility complex molecules.

Authors:  U Moebius; L K Clayton; S Abraham; A Diener; J J Yunis; S C Harrison; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

5.  The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure.

Authors:  U Moebius; L K Clayton; S Abraham; S C Harrison; E L Reinherz
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

6.  CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics.

Authors:  Andreas Schweizer; Peter Rusert; Livia Berlinger; Claudia R Ruprecht; Axel Mann; Stéphanie Corthésy; Stuart G Turville; Meropi Aravantinou; Marek Fischer; Melissa Robbiani; Patrick Amstutz; Alexandra Trkola
Journal:  PLoS Pathog       Date:  2008-07-25       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.